Alzheimer Disease research hub

I9X-MC-MTAE: Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer’s Disease

This study is looking into a new medication for people in the early stages of Alzheimer's disease. Researchers want to see if the medication, called LY3372689, is safe, has side effects, and if it helps improve or slow down symptoms compared to a dummy treatment.

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

This study, ALTITUDE-AD, is testing a new medicine called sabirnetug to see if it can slow down memory and thinking problems in people with early Alzheimer's disease. Participants will receive either sabirnetug or a dummy medicine every four weeks to compare their effects.

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

This study is testing a new medicine, JNJ-64042056, for people who are at very early stages of Alzheimer's disease. Researchers want to see if the medicine can stop a specific brain protein, called tau, from building up and spreading, which is linked to the condition.

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

This study is testing a new drug, NIO752, to see if it can reduce a protein called tau in the brains of people with early Alzheimer's disease. Too much tau builds up in Alzheimer's and causes damage. We want to see if this drug can help prevent that.

A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)

This study is testing a new medicine called MK-1167 for people with Alzheimer's disease. Researchers want to see if it can improve memory and thinking when taken with standard treatment and if it's safe and well-tolerated.

Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease

This study investigates a new imaging technique, Cortical Disarray Measurement (CDM), to improve the early diagnosis of Alzheimer's disease in people with memory problems. It aims to see if CDM can identify early changes and how these relate to memory over two years, helping us better understand and diagnose Alzheimer’s.

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

This study looks at a new medicine for agitation in people with Alzheimer's. It aims to see if an experimental drug, given as capsules, is safe and works well over a long time for those who've been in similar studies before.

Longitudinal Early-onset Alzheimer's Disease Study Protocol

This study looks at how early-onset Alzheimer's disease develops over time. It compares people with this condition to those without it, gathering information on memory, brain scans, and other health markers to better understand the disease.

Optical Neuroimaging and Cognition

This study looks at how brain oxygen and energy use change in people with Alzheimer's, Lewy Body Dementia, and Mild Cognitive Impairment. We're using new, gentle scanning methods to better understand these conditions and find ways to help with diagnosis and monitoring.

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

This study is looking at a new medicine called donanemab for people in the early stages of Alzheimer's disease. Researchers want to find out if it's safe and effective at treating the condition. Some people will get the medicine, and others a dummy treatment.

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

This study is testing a new medication called donanemab for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and helps improve or slow memory and thinking problems. It's a key step in understanding potential new treatments for this condition.

Trial-Ready Cohort-Down Syndrome (TRC-DS)

This study looks at adults with Down syndrome to understand how Alzheimer's disease develops. It aims to find better ways to measure changes in the brain for future drug trials, helping to speed up the search for effective treatments.

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

This study looks at a new medicine called LY3954068 for people with early Alzheimer's disease. Researchers want to see if it's safe, how it moves through the body, and if it affects signs of the disease. Participants will receive the medicine or a dummy treatment through an injection into the spinal fluid.

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

This study is testing a new medicine, AR1001, for people in the early stages of Alzheimer's disease. We want to see if it's safe and helps improve or slow down symptoms compared to a dummy medicine.

Detecting Early Alzheimer's Using MR

This study is testing a new, safer MRI scan called glucoCEST to find early signs of Alzheimer's disease. Currently, detecting early Alzheimer's can be tricky. This new scan looks at how the brain uses sugar without using radiation, hoping to find the disease sooner and help people get treatment earlier.

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

This study is looking into a new treatment called KarXT + KarX-EC for agitation (feeling restless or upset) in people with Alzheimer's disease. It wants to see if the treatment is safe and if it helps reduce agitation.

IONA Longitudinal Cohort Study

The IONA study in Scotland is looking at how memory and thinking decline. Researchers are collecting health, lifestyle, and genetic information from people over 50. The goal is to better understand dementia and eventually help develop new treatments for conditions like Alzheimer's disease.

I5T-MC-AACI: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

This study is looking at a new treatment called KarXT + KarX-EC for psychosis, which can affect people with Alzheimer's disease. Researchers want to see if this treatment is safe and helps reduce psychotic symptoms like hallucinations or delusions in individuals aged 55 to 90.